FOUNTAIN HILLS, Ariz., Jan. 13, 2011 /PRNewswire/ — Sunridge
International (OTC Bulletin Board:
SNDZ), announced today that it plans to open company owned
glaucoma clinics for the use of its patented treatment Pneumatic
Trabeculoplasty (PNT).
As a manufacturer, Sunridge currently relies on its distributor
network for sales. Though the company is in the process of
expanding its distributor network, it is still reliant on others to
provide profitability for the company. It is the company’s
intent to take advantage of its patented procedure by initiating
glaucoma clinics under its direct control. By doing so,
Sunridge can capitalize not only on the sales of its equipment and
disposable product line to others, but also a direct revenue source
from our clinics for the medical treatment itself.
Sunridge is currently raising money to open its first clinic.
Based on past experience our projections for the clinic would
indicate that it would be cash flow positive by its fourth month of
operation. Once successful with the first clinic, Sunridge
intends to raise capital for the rapid expansion of additional
company owned clinics. This new direction in the company’s
business plan allows us to take direct charge of our future and
accelerate profitability for the company.
Glaucoma is the second leading cause of blindness, affecting
over 70 million people worldwide. PNT has been proven (through
studies completed over the last 10 yrs) to be a safe, effective,
non-invasive and a cost effective alternative for treatment for
glaucoma and ocular hypertension. The 2-minute treatment has been
developed, patented, and distributed by Sunridge International,
wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.CONTACT:Jeff Smith
Sunridge InternationalT: +1-480-837-6165e-mail: ‘/>”/>
